New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2013
08:29 EDTSRPTSarepta's eteplirsen accelerated approval could be denied, TheStreet.com reports
According to TheStreet.com, accelerated approval for Sarepta's (SRPT) eteplirsen, a novel experimental drug for Duchenne Muscular Dystrophy, will be denied by the FDA. Instead, TheStreet says it is more likely Sarepta will be required to perform a larger pivotal study prior to submitting the drug for FDA review. Reference Link
News For SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for SRPT

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use